Lingkang Pharmaceutical: Revenue of 365 million yuan in 2025, with an expected net loss of 127 million yuan.

Lingkang Pharmaceutical announced that it is expected to achieve annual operating income of approximately 365 million yuan in 2025, a year-on-year decrease of about 3.89%; after deducting related income, the revenue will be around 345 million yuan, a year-on-year decrease of about 6.64%. The net profit attributable to the owners of the parent company is expected to be around -127 million yuan, a year-on-year decrease of about 2.88%; the non-GAAP net profit is expected to be around -147 million yuan, a year-on-year decrease of about 18.41%. The main reasons for the performance change are that some anti-infection products are in transition between old and new public bidding periods, the prices of winning bid products have decreased, competition in cardiovascular and cerebrovascular products has intensified, low capacity utilization, and a significant increase in revenue from pharmaceutical agent and distribution business.